ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Resmed Inc (NYSE:RMD) traded in a range yesterday that spanned from a low of $161.84 to a high of $164.45. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $161.98...
ResMed (RMD) launches its first tube-up, full-face CPAP mask, thus completing its full-face mask portfolio.
ResMed (NYSE: RMD) (ASX: RMD) today introduced AirFit F30i, its first tube-up full face CPAP mask, rounding out the most complete full face mask portfolio on the market.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating potential claims against certain officers and directors of ResMed, Inc. (NYSE: RMD) on behalf of long-term stockholders....
Shareholder rights law firm Robbins LLP is investigating whether certain officers and directors of ResMed Inc. (NYSE: RMD) breached their fiduciary duties to shareholders. ResMed develops, manufactures,...
ResMed (NYSE: RMD) (ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2020 on Thursday, January 30, 2020, after the New York Stock Exchange...
Resmed Inc (NYSE:RMD) traded in a range yesterday that spanned from a low of $157.01 to a high of $157.75. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $156.12...
ResMed (NYSE: RMD, ASX: RMD) today announced that Mick Farrell, chief executive officer, will present at the 38th Annual J.P. Morgan Annual Healthcare Conference on Monday, January 13, 2020, beginning...
NUVA vs. RMD: Which Stock Is the Better Value Option?
Tandem Diabetes' (TNDM) products under development comprise AID systems, a next-generation hardware platform and connected (mobile) health offerings.
Intersect ENT (XENT) recently closes its ENCORE study, a small 50-patient open label program designed to evaluate the safety of the repetitive use of SINUVA.
Bruker (BRKR) is reaping solid synergy benefits from the acquisitions of Anasys, JPK and Alicona.
Zimmer Biomet (ZBH) is optimistic about maintaining growth momentum on several recent positive developments.
Neogen Corporation (NEOG) disappoints investors with dismal second-quarter fiscal 2020 results. However, the Food Safety segment showcased a robust performance.
Banking on the three key trends, we zero in on six MedTech stocks that are likely to deliver stellar performance in 2020.
GNC Holdings (GNC) launches natural ingredient-based energy drink MAD PONY ENERGY.
Neogen's (NEOG) Soleris test gets clearance from the AOAC, paving the way for efficient prevention of food contamination.
Zimmer Biomet (ZBH) is executing well within its priority areas like quality remediation, supply recovery efforts and product rollouts.
Medtronic (MDT) strengthens its robotics platform with the receipt of regulatory approval and the subsequent upgradation of its enabling technology portfolio.